KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Adaptive Biotechnologies (ADPT) EPS (Weighted Average and Diluted): 2020-2024

Historic EPS (Weighted Average and Diluted) for Adaptive Biotechnologies (ADPT) over the last 5 years, with Dec 2024 value amounting to -$1.08.

  • Adaptive Biotechnologies' EPS (Weighted Average and Diluted) rose 127.27% to $0.06 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.53, marking a year-over-year increase of 60.45%. This contributed to the annual value of -$1.08 for FY2024, which is 30.77% up from last year.
  • As of FY2024, Adaptive Biotechnologies' EPS (Weighted Average and Diluted) stood at -$1.08, which was up 30.77% from -$1.56 recorded in FY2023.
  • In the past 5 years, Adaptive Biotechnologies' EPS (Weighted Average and Diluted) registered a high of -$1.08 during FY2024, and its lowest value of -$1.56 during FY2023.
  • Its 3-year average for EPS (Weighted Average and Diluted) is -$1.35, with a median of -$1.40 in 2022.
  • Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first tumbled by 33.33% in 2021, then surged by 30.77% in 2024.
  • Over the past 5 years, Adaptive Biotechnologies' EPS (Weighted Average and Diluted) (Yearly) stood at -$1.11 in 2020, then plummeted by 33.33% to -$1.48 in 2021, then climbed by 5.41% to -$1.40 in 2022, then decreased by 11.43% to -$1.56 in 2023, then skyrocketed by 30.77% to -$1.08 in 2024.